2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Value, Diseases, Bleeding and Clotting, Immunology, Infectious Diseases, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1608 Early versus late relapse following frontline therapy for acute promyelocytic leukemia: A single-center study

Yuya Sasaki, MD, PhD, Mina Abdelmalek, MD2, Farah Al Haj, MD3, Wei Ying Jen, BM BCh, FRCPath4, Tapan Kadia I, MD5, Gautam Borthakur, MD6, Musa Yilmaz, MD7, Jennifer Marvin-Peek, MD8, Sherry Pierce, BSN, RN9, David McCue10, Elias Jabbour, MD11, Courtney DiNardo, MD, MSCE12, Naval Daver, MD13, Naveen Pemmaraju, MD14, Nitin Jain, MD15, Alessandra Ferrajoli III, MD16, William G. Wierda, MD, PhD17, Guillermo Garcia-Manero, MD18, Hagop Kantarjian, MD19, Farhad Ravandi, MD20
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 Ochsner MD Anderson Cancer Center, Gretna, Louisiana, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background:

The introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has transformed the treatment landscape of acute promyelocytic leukemia (APL), resulting in long-term remission in more than 90% of patients. Consequently, available data on the clinical characteristics and outcomes of patients who relapse after frontline ATRA/ATO-based therapy remain limited. We therefore evaluated patients who experienced relapse, with a particular focus on differences between early and late relapse.

Methods:

We retrospectively reviewed patients with APL who were treated at our institution with ATRA plus ATO-based regimens from February 2002 to August 2025 and identified patients who experienced relapse. Early relapse was defined as relapse occurring within 12 months of the initial diagnosis, whereas late relapse was defined as relapse occurring 12 months or more after the initial diagnosis.

Baseline characteristics, re-induction therapy, response, and survival outcomes were compared between the two groups. Continuous variables were compared using the Wilcoxon rank-sum test, and categorical variables were compared using Fisher's exact test. Overall survival was estimated using the Kaplan–Meier method.

Results:

Among 386 patients who received frontline ATRA/ATO-based therapy, 13 (3.4%) experienced relapse, including 9 with early relapse and 4 with late relapse. Of the 13 patients, 4 had standard-risk disease and 9 had high-risk disease at first diagnosis. No significant differences were observed between the two groups with respect to age, sex, ethnicity, presenting white blood cell count at diagnosis, FLT3 mutation status, or PML::RARA transcript isoform. Additional cytogenetic abnormalities at treatment initiation were identified in four patients, all of whom experienced early relapse: ider(17)(q10)t(15;17) in two patients, del(7)(q32q36) in one patient, and monosomies 13 and 14 in one patient (p = 0.20).

Re-induction therapy most commonly consisted of ATRA- and ATO-based regimens in both groups, used in 5 patients (38.5%). Complete remission after re-induction therapy was achieved in 7 patients with early relapse and 4 patients with late relapse. In second remission, stem cell transplantation (SCT) was performed in two patients with early relapse (one autologous and one haploidentical allogeneic SCT) and one patient with late relapse (allogeneic SCT).


At a median follow-up of 9.5 years after relapse, the 10-year overall survival was 43.8% (95% confidence interval [CI], 6.0% - 78.5%) in the early-relapse group and 100% (95% CI, 100% - 100%) in the late-relapse group (p = 0.097).

 

Conclusions:

Relapse following frontline ATRA/ATO-based therapy was uncommon, occurring in only 3.4% of patients. Additional cytogenetic abnormalities at diagnosis were observed exclusively among patients with early relapse. Future studies are warranted to elucidate the underlying molecular mechanisms of relapse.

Yuya Sasaki, MD, PhD: No relevant conflicts of interest to declare.